Clinical Trial Details


Research Study Summary

New Investigational Medication for Relapsing Remitting Multiple Sclerosis (RRMS)


This is a 12 month open label study to evaluate the patient retention rate of Fingolimod vs. approved 1st-line disease modifying therapies in adults who are in early stages of treatment for RRMS.

Patient Inclusion Criteria:

  • 18-65
  • Patients naїve to treatment OR who have been treated with no more than one DMT; total treatment less than or equal to 5 years
  • For safety, certain cardiovascular conditions and medications are excluded; this will be reviewed with the study nurse

To Learn more

CW ID: 182094
Date Last Changed: July 18, 2013

Clinical Trial Snapshot

Both Male and Female
18 to 65 Years
Overall Status
12 Months
Facility Type


Alpine Clinical Research Center
1000 Alpine Avenue , Suite 200
Boulder, CO 80304
Phone: 303-443-7229

View Map

Research Center Information:

Alpine Clinical Research Center

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.